Hoffmann-La Roche: Melanoma trials

The registry lists 57 Melanoma studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 34 have results posted.

Early Phase 1 1Phase 1 28Phase 2 18Phase 3 7Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)CompletedNCT05116202Phase 1/2Results posted
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
• Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal MelanomaCompletedNCT04091217Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.CompletedNCT03815058Phase 2Results posted
• A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid TumorsCompletedNCT03708328Phase 1Results posted
• A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesCompletedNCT03625141Phase 2Results posted
• A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type MelanomaTerminatedNCT03273153Phase 3Results posted
• Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced MelanomaCompletedNCT03178851Phase 1Results posted
• A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaCompletedNCT02908672Phase 3Results posted
• A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical StudiesCompletedNCT02829775Phase 2/3Results posted
• Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic MelanomaCompletedNCT02663232Results posted
• A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT02457793Phase 1Results posted
• A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic MelanomaCompletedNCT01910181Phase 1Results posted
• A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic MelanomaCompletedNCT01765569Phase 1Results posted
• A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)CompletedNCT01765543Phase 1Results posted
• Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor SamplesCompletedNCT01744860Results posted
• A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaCompletedNCT01689519Phase 3Results posted
• A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant MelanomaCompletedNCT01667419Phase 3Results posted
• Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600ETerminatedNCT01586195Phase 2Results posted
• BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 MutationsTerminatedNCT01519323Phase 1Results posted
• A Study of Vemurafenib in Metastatic Melanoma Participants With Brain MetastasesCompletedNCT01378975Phase 2Results posted
• A Study of Vemurafenib in Participants With Metastatic MelanomaCompletedNCT01307397Phase 3Results posted
• A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic MelanomaCompletedNCT01271803Phase 1Results posted
• A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic MelanomaCompletedNCT01264380Phase 1Results posted
• A Study of RO5185426 in Previously Treated Melanoma Patients With Brain MetastasesCompletedNCT01253564Phase 2Results posted
• A Study of RO5185426 in Patients With Metastatic MelanomaCompletedNCT01248936Phase 2Results posted
• A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic MelanomaCompletedNCT01164891Phase 1Results posted
• A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic MelanomaCompletedNCT01164007Phase 2Results posted
• A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic MelanomaCompletedNCT01107418Phase 1Results posted
• A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic MelanomaCompletedNCT01069627Phase 2Results posted
• A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)CompletedNCT01006980Phase 3Results posted
• A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic MelanomaCompletedNCT01001299Phase 1Results posted
• A Study of Vemurafenib in Previously Treated Patients With Metastatic MelanomaCompletedNCT00949702Phase 2Results posted
• A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic MelanomaCompletedNCT00434252Phase 2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT05581004Phase 1
• A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic MelanomaCompletedNCT05419388Phase 2
• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruitingNCT04835805Phase 1
• A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive MelanomasCompletedNCT04551352Phase 1
• Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsActive, not recruitingNCT04140500Phase 1/2
• A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic MelanomaCompletedNCT03875079Phase 1
• Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid TumorsTerminatedNCT03454243Early Phase 1
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT03289962Phase 1
• A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])CompletedNCT03139513
• A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced MelanomaCompletedNCT02768207Phase 2
• A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady StateCompletedNCT02608034Phase 1
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active, not recruitingNCT02568267Phase 2
• Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive MalignanciesCompletedNCT02441465Phase 1
• An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic MelanomaCompletedNCT02143999
• An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)CompletedNCT01990248
• An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic MelanomaCompletedNCT01898585Phase 4
• A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyCompletedNCT01851824Phase 1
• A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyCompletedNCT01849666Phase 1
• A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic MalignanciesCompletedNCT01844674Phase 1
• A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic MelanomaWithdrawnNCT01765556Phase 1
• A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic MelanomaCompletedNCT01656642Phase 1
• A Study of DEDN6526A in Patients With Metastatic or Unresectable MelanomaCompletedNCT01522664Phase 1
• A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With MelanomaTerminatedNCT00272415Phase 1